Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to ADX-097 in ANCA-Associated Vasculitis

Trial Profile

A Phase 2 Study to ADX-097 in ANCA-Associated Vasculitis

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADX-097 (Primary)
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Adverse reactions

Most Recent Events

  • 13 Aug 2024 New trial record
  • 08 Aug 2024 According to a Q32 Biomedia release, the company expects to initiate this trial in the first half of next year, with topline results expected in the second half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top